Vaillant

Researchers are investigating ASP2138, a potential treatment targeting the claudin 18.2 CLDN18.2 protein found on cells in the digestive system and some tumors. This study focuses on adults 18 years or older with stomach cancer, gastroesophageal junction GEJ cancer, or pancreatic cancer that is locally advanced unresectable or metastatic and expresses the CLDN18.2 marker. The study aims to understand how ASP2138 is processed by the body and to identify suitable dosing when given alone or combined with standard cancer treatments. The study includes two phases Phase 1 involves giving ASP2138 in escalating doses either intravenously or by subcutaneous injection, alone or with standard treatments such as pembrolizumab and mFOLFOX6, ramucirumab and paclitaxel, or mFOLFIRINOX depending on the cancer type. Phase 1b uses doses determined in Phase 1 to treat participants with these cancers, again either as monotherapy or combined with standard treatments. An end-of-treatment visit occurs 7 days after the final dose or if treatment is stopped early. Participants will have their safety and tolerance to ASP2138 monitored closely through assessments including adverse events, laboratory and vital sign tests, electrocardiograms, and physical exams over several months. Researchers will also measure ASP2138 blood levels, tumor response, and changes in tumor markers. The study follows participants for up to 27 months to gather comprehensive data on treatment effects and safety.

Researchers are evaluating the safety and effectiveness of a new oral drug called daraxonrasib compared to the chemotherapy drug docetaxel in patients with non-small cell lung cancer NSCLC that has a specific RAS mutation. This Phase 3, randomized, open-label study aims to see if daraxonrasib can improve progression-free survival or overall survival in patients who have already received prior treatments. The study focuses on patients with locally advanced or metastatic NSCLC who cannot be cured with surgery or radiation. Participants will be randomly assigned in equal groups to receive either daraxonrasib tablets or docetaxel by intravenous infusion. The treatments will be given according to the study plan, and participants will be monitored over about four years. The study includes careful assessment of response to treatment, safety, quality of life, and drug characteristics during this period. During the trial, participants will undergo regular evaluations including imaging scans to measure tumor size, assessments of side effects, blood tests to check organ function, and questionnaires about quality of life. Researchers will track how long patients live without disease progression and overall survival, along with treatment effects and tolerability. This follow-up and monitoring will continue for up to approximately four years, ensuring comprehensive data collection throughout the study duration.